| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.097 | 0.05 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.086 | 0.05 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.31 | 0.05 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.05 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.074 | 0.06 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.07 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.07 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.07 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |